ALK and cancer: Here, we were able to demonstrate that the efficiency of ALA-PDT could be enhanced by treatment of cancer cells with Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase (ALK).